Validation of the SHOX2/PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease.
about
Methylated DNA/RNA in Body Fluids as Biomarkers for Lung Cancer.The evidence base for circulating tumour DNA blood-based biomarkers for the early detection of cancer: a systematic mapping review.DNA Methylation Analysis of the SHOX2 and RASSF1A Panel in Bronchoalveolar Lavage Fluid for Lung Cancer Diagnosis.Whole blood FPR1 mRNA expression predicts both non-small cell and small cell lung cancer.Lung Cancer Field Cancerization: Implications for Screening by Low-Dose Computed Tomography.Cell-Free DNA Methylation of Selected Genes Allows for Early Detection of the Major Cancers in Women
P2860
Validation of the SHOX2/PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 August 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Validation of the SHOX2/PTGER4 ...... and Nonmalignant Lung Disease.
@en
Validation of the SHOX2/PTGER4 ...... and Nonmalignant Lung Disease.
@nl
type
label
Validation of the SHOX2/PTGER4 ...... and Nonmalignant Lung Disease.
@en
Validation of the SHOX2/PTGER4 ...... and Nonmalignant Lung Disease.
@nl
prefLabel
Validation of the SHOX2/PTGER4 ...... and Nonmalignant Lung Disease.
@en
Validation of the SHOX2/PTGER4 ...... and Nonmalignant Lung Disease.
@nl
P2093
P2860
P1476
Validation of the SHOX2/PTGER4 ...... and Nonmalignant Lung Disease.
@en
P2093
Anne Schlegel
Denise Kottwitz
Gunter Weiss
Reimo Tetzner
Thomas König
P2860
P356
10.1016/J.JTHO.2016.08.123
P577
2016-08-17T00:00:00Z